Understanding and overcoming mechanisms of tumor resistance
Guest Editor:Brent Hanks, Assistant Professor, Medicine, Pharmacology & Cancer Biology at Duke University
Assistant Professor, Medicine, Pharmacology & Cancer Biology at Duke University
Brent A. Hanks, M.D., Ph.D. is the William Dalton Family Assistant Professor of Medical Oncology in the Departments of Medicine and Pharmacology and Cancer Biology at Duke University with a dual appointment with the Duke Cancer Institute. Dr. Hanks completed his medical degree along with a Ph.D. in tumor immunology while in the Medical Scientist Training Program at Baylor College of Medicine. Dr. Hanks went on to complete his internal medicine residency training and his hematology and oncology fellowship training at Duke University. He now manages a basic and translational research lab focusing on understanding biochemical mechanisms of tumor-mediated immune evasion and immunotherapy resistance in cancer. More recently, his lab is also exploring the underlying mechanisms associated with immunotherapy-associated toxicities. In addition to his research efforts, he is also a medical oncologist and manages patients with advanced skin cancers including melanoma and Merkel cell carcinoma. Using an array of experimental techniques, his labs' research goals are to develop novel strategies to enhance the efficacy of checkpoint inhibitor and vaccine immunotherapy while also developing predictive biomarkers to better guide the management of cancer patients with immunotherapeutic agents.